Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
07 oct. 2024 07h05 HE
|
Virios Therapeutics
Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development...
Virios Therapeutics Announces Second Quarter 2024 Financial Results
08 août 2024 09h15 HE
|
Virios Therapeutics
- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman...
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
23 juil. 2024 09h15 HE
|
Virios Therapeutics
- Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients,...
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
22 mai 2024 13h30 HE
|
Virios Therapeutics
ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel...
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
19 mai 2024 20h53 HE
|
Virios Therapeutics
ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel...
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
17 mai 2024 16h10 HE
|
Virios Therapeutics
ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel...
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h45 HE
|
Virios Therapeutics
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call...
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
02 mai 2024 09h15 HE
|
Virios Therapeutics
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
26 mars 2024 09h15 HE
|
Virios Therapeutics
- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses...
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
29 févr. 2024 09h15 HE
|
Virios Therapeutics
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...